GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Insider Ownership

Tourmaline Bio (Tourmaline Bio) Insider Ownership : 6.17 % (As of May. 26, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Tourmaline Bio's insider ownership is 6.17%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Tourmaline Bio's Institutional Ownership is 13.86%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Tourmaline Bio's Float Percentage Of Total Shares Outstanding is 89.14%.

Tourmaline Bio Insider Ownership Historical Data

The historical data trend for Tourmaline Bio's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio Insider Ownership Chart

Tourmaline Bio Historical Data

The historical data trend for Tourmaline Bio can be seen below:

2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Insider Ownership 7.76 7.79 7.78 6.17 6.17 6.17 6.17

Tourmaline Bio Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Insider Ownership
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.